



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

27th March, 2025

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulations 29(2) of the SEBI (Substantial acquisition of shares and Takeovers) Regulations 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015

Ref :- Natco Pharma Limited

Please find enclosed herewith the disclosures received from Mr. Sanjay Nannapaneni, Member of Promoter Group under Regulations 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 pertaining to the transmission of Shares from Late Ramakrishna Rao Nannapaneni, Member of Promoter Group.

This is for your information and records.

Thanking you

Yours faithfully
For NATCO Pharma Limited


Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

27th March, 2025

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulations 29(2) of the SEBI (Substantial acquisition of shares and Takeovers) Regulations 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015

Ref :- Natco Pharma Limited

With reference to the above cited subject, I hereby disclose that 2,86,910 equity shares of Rs.2/- each held by Late Ramakrishna Rao Nannapaneni, Member of Promoter Group of NATCO Pharma Limited were transmitted to me on 26th March, 2025.

The said shares were transmitted to me pursuant to the registered Will Deed of my father via Off-Market Transaction by using “Code 21 i.e., Transfer from Nominee/Surviving holder to beneficiary” of National Securities and Depositories Limited and Sri V.C. Nannapaneni was merely acting as the facilitator of the said transmission process, since he was the nominee to the shares.

Accordingly, the disclosures pertaining to the said shares under Regulations 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015 were enclosed.

This is for your information and records.

Thanking you
Yours faithfully



Sanjay Nannapaneni

C.C to:
The Company Secretary, NATCO Pharma Limited

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	NATCO Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Sanjay Nannapaneni		
Whether the acquirer belongs to Promoter/Promoter group	Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Ltd & NSE		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	40,000	0.02	0.02
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	40,000	0.02	0.02
Details of acquisition/sale/ Donation			
a) Shares carrying voting rights acquired/sold			
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	2,86,910	0.16	0.16
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+-d)	2,86,910	0.16	0.16



After the acquisition/sale, holding of: a) Shares carrying voting rights b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d)	3,26,910	0.18	0.18
	3,26,910	0.18	0.18
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc). Off-Market (as per registered Will Deed, the shares were received from the Nominee of the deceased Shareholder to the legal heir)			
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	26 March, 2025		
Equity share capital / total voting capital of the TC before the said acquisition / sale	17,91,09,870		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	17,91,09,870		
Total diluted share/voting capital of the TC after the said acquisition	17,91,09,870		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



Signature of the acquirer / seller / Authorised Signatory

Place: USA

Date: 27 March, 2025
